NCT01495793View on ClinicalTrials.gov

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Restless Legs Syndrome
Interventions
DRUG

Rotigotine

"Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied."

Trial Locations (12)

Unknown

Sp1004 006, Little Rock

Sp1004 012, Los Angeles

Sp1004 009, Orange

Sp1004 005, Washington D.C.

Sp1004 014, Spring Hill

Sp1004 013, Indianapolis

Sp1004 001, Destrehan

Sp1004 015, St Louis

Sp1004 007, West Seneca

Sp1004 002, Cincinnati

Sp1004 016, West Chester

Sp1004 003, Austin

All Listed Sponsors
lead

UCB BIOSCIENCES, Inc.

INDUSTRY

NCT01495793 - Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome | Biotech Hunter | Biotech Hunter